Tenofovir alafenamide is a Small Molecule owned by Gilead Sciences, and is involved in 54 clinical trials, of which 37 were completed, and 17 are ongoing.

Tenofovir alafenamide (Vemlidy, GS-7340) acts by inhibiting reverse transcriptase through competing with the natural substrate deoxyadenosine 5’-triphosphate and, after incorporation into DNA, and DNA chain termination. It is a synthetic antiviral acyclic nucleotide analogue of adenosine 5-monophosphate. It stops the virus making DNA and prevents it from multiplying and spreading leads to prevention of hepatitis B virus infections.

The revenue for Tenofovir alafenamide is expected to reach a total of $14.8bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Tenofovir alafenamide NPV Report.

Tenofovir alafenamide is originated and owned by Gilead Sciences.

Tenofovir alafenamide Overview

Tenofovir alafenamide (Vemlidy, Willid) acts as an anti viral agent. It is formulated as film coated tablets, coated tablets for oral route of administration. It is indicated for the treatment of chronic hepatitis B virus (HBV) infection in adults with compensated liver disease, and in adolescents aged 12 years and older.

It is under development for the treatment of relapsing remitting multiple sclerosis.

It was also under development for HIV infection.

Gilead Sciences Overview

Gilead Sciences (Gilead) is a research-based biopharmaceutical company. It is engaged in the discovery, development and commercialization of medicines for the treatment of cardiovascular, hematological and respiratory diseases, inflammation, liver diseases, cancer and human immunodeficiency virus (HIV) infection. The company sells its products through subsidiaries and distributors in Europe, the Americas, Asia-Pacific, the Middle East and Africa. It has manufacturing facilities in Edmonton, Alberta, Canada; Foster City, San Dimas, Oceanside, California; and Cork, Ireland among others. The company has partnerships with universities, medical research institutions and global pharmaceutical leaders to develop new drugs. Gilead is headquartered in Foster City, California, the US.

The company reported revenues of (US Dollars) US$27,305 million for the fiscal year ended December 2021 (FY2021), an increase of 10.6% over FY2020. In FY2021, the company’s operating margin was 36.3%, compared to an operating margin of 16.5% in FY2020. In FY2021, the company recorded a net margin of 22.8%, compared to a net margin of 0.5% in FY2020. The company reported revenues of US$7,042 million for the third quarter ended September 2022, an increase of 12.5% over the previous quarter.

Quick View – Tenofovir alafenamide

Report Segments
  • Innovator (Non-NME)
Drug Name
  • Tenofovir alafenamide
Administration Pathway
  • Oral
Therapeutic Areas
  • Central Nervous System
  • Infectious Disease
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.